EUCTR2009-016879-29-ESActive, not recruitingPhase 1
GR015: Randomised double-blind phase III study of NGR-hTNF plus best investigator's choice (BIC) versus placebo plus BIC in previously treated patients with advanced malignant pleural mesothelioma (MPM) - NGR015
MOLMED0 sites390 target enrollmentStarted: May 10, 2012Last updated:
Trial Snapshot
- Phase
- Phase 1
- Status
- Active, not recruiting
- Sponsor
- Enrollment
- 390
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional clinical trial of medicinal product
Eligibility Criteria
- Sex
- All
Inclusion Criteria
- •1.Age ? 18 years
- •2. Histologically or cytological confirmed malignant pleural mesothelioma of any of the following subtype:
- •epithelial, sarcomatoid, mixed, or unknown
- •3. Prior treatment with no more than one sistemic pemetrexed-based chemotherapy regimen administered
- •for advanced or metastatic disease. Prior use of a biological agent in combination with a pemetrexed based
- •regimen and prior administration of intrapleural cytotoxic agents are allowed.Patients who have previously received anthracyclines should not receive doxorubicin.
- •4. ECOG Performance Status 0 - 2
- •5. Life expectancy of ?12 weeks
- •6. Adequate baseline bone marrow, hepatic and renal function, defined as follows:
- •a. Neutrophils ? 1.5 x 109/L; platelets ? 100 x 109/L; hemoglobin ? 9 g/dL
- •b. Bilirubin ? 1.5 x ULN
- •c. AST and/or ALT ? 2.5 x ULN in absence of liver metastasis or ? 5 x ULN in presence of liver metastasis
- •d. Serum creatinine < 1.5 x ULN
- •7. Measurable or non-measurable disease according to MPM-modified RECIST criteria
- •8. Patients may have had prior therapy providing the following conditions are met:
- •a. Surgery: wash-out period of 14 days
- •b.Systemic anti-tumor and radiation therapy: wash-out period of 28 days
- •9. Patients must give written informed consent to participate in the study
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 195
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 195
Exclusion Criteria
- •1. Patients must not receive any other investigational agents while on study
- •2. Patients with myocardial infarction within the last six months, unstable angina, New York Heart association (NYHA) grade II or greater congestive heart failure, or serious cardiac arrhythmia requiring medication
- •3. Uncontrolled hypertension
- •4. QTc interval (congenital or acquired) > 450 ms
- •5. History or evidence upon physical examination of CNS disease unless adequately treated (e.g., primary brain tumor, any brain metastasis, seizure not controlled with standard medical therapy, or history of stroke)
- •6. Patients with active or uncontrolled systemic disease/infections or with serious illness or medical conditions, which is incompatible with the protocol
- •7. Known hypersensitivity/allergic reaction to human albumin preparations or to any of the excipients
- •8. Any psychological, familial, sociological or geographical condition potentially tampering compliance with the study protocol
- •9. Pregnancy or lactation.
Investigators
Similar Trials
Active, not recruiting
Phase 1
Study of efficacy and safety of the compound NGR-hTNF in patient with advanced malignant pleural mesotheliomaEUCTR2009-016879-29-NLMOLMED390
Completed
Phase 3
GR015: Randomised double-blind phase III study of NGR-hTNF plus best investigator's choice (BIC) versus placebo plus BIC in previously treated patients with advanced malignant pleural mesothelioma (MPM)Pleural Tumor / advanced malignant pleural mesothelioma10027412NL-OMON37673COMPANY IS INNOPHARMA S.R.L, ITALY45
Active, not recruiting
Phase 1
Study of efficacy and safety of the compound NGR-hTNF in patient with advanced malignant pleural mesotheliomaAdvanced malignant pleural mesothelioma previuosly treated with a pemetrexed based chemotherapy regimenMedDRA version: 15.0Level: PTClassification code 10035605Term: Pleural mesothelioma malignant advancedSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2009-016879-29-BEMOLMED390
Active, not recruiting
Phase 1
Study of efficacy and safety of the compound NGR-hTNF in patient with advanced malignant pleural mesotheliomaAdvanced malignant pleural mesothelioma previuosly treated with a pemetrexed based chemotherapy regimenMedDRA version: 14.1Level: PTClassification code 10035605Term: Pleural mesothelioma malignant advancedSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2009-016879-29-SEMOLMED390
Active, not recruiting
Phase 1
Study of efficacy and safety of the compound NGR-hTNF in patient with advanced malignant pleural mesotheliomapplicableEUCTR2009-016879-29-GBMOLMED400